Review the safety of Covid-19 mRNA vaccines: a review.
Review the safety of Covid-19 mRNA vaccines: a review.
复制标题
DOI：
10.1186/s13037-021-00291-9
复制
发表时间：
2021-05-01
影响因子：
3.7
通讯作者：
Stahel VP
中科院分区：
文献类型：
--
作者：
Anand P;Stahel VP
2019新型冠状病毒病（COVID-19）在大流行的第一年内已感染全球超过1亿人。仅在美国，死亡人数就超过50万人，控制这一大流行病的前提是在全球范围内实现群体免疫。这意味着至少70- 80%的人口必须实现对严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）的主动免疫，无论是由于先前的COVID-19感染还是通过接种SARS-CoV-2疫苗。2020年12月，前两款疫苗在美国通过紧急使用授权获得FDA批准。这些疫苗基于mRNA疫苗平台，由Pfizer/BioNTech和Moderna开发。已发表的安全性和有效性试验报告称，两次间隔给药后的有效性高达94- 95%，副作用有限，不良反应发生率低。疫苗开发的快速步伐和潜在的长期不良影响的不确定性在国际社会引起了对mRNA疫苗的某种程度的犹豫。成功的疫苗接种运动取决于在适当的储存条件下广泛获得疫苗、部署足够数量的疫苗接种员以及民众愿意接种疫苗。因此，澄清与疫苗安全性相关的客观数据，包括已知的副作用和潜在的不良反应，是非常重要的。本综述旨在提供与SARS-CoV-2 mRNA疫苗安全性和有效性相关的最新科学状况。
The novel coronavirus disease 2019 (COVID-19) has infected more than 100 million people globally within the first year of the pandemic. With a death toll surpassing 500,000 in the United States alone, containing the pandemic is predicated on achieving herd immunity on a global scale. This implies that at least 70-80 % of the population must achieve active immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), either as a result of a previous COVID-19 infection or by vaccination against SARS-CoV-2. In December 2020, the first two vaccines were approved by the FDA through emergency use authorization in the United States. These vaccines are based on the mRNA vaccine platform and were developed by Pfizer/BioNTech and Moderna. Published safety and efficacy trials reported high efficacy rates of 94-95 % after two interval doses, in conjunction with limited side effects and a low rate of adverse reactions. The rapid pace of vaccine development and the uncertainty of potential long-term adverse effects raised some level of hesitation against mRNA vaccines in the global community. A successful vaccination campaign is contingent on widespread access to the vaccine under appropriate storage conditions, deployment of a sufficient number of vaccinators, and the willingness of the population to be vaccinated. Thus, it is important to clarify the objective data related to vaccine safety, including known side effects and potential adverse reactions. The present review was designed to provide an update on the current state of science related to the safety and efficacy of SARS-CoV-2 mRNA vaccines.
登录
查看更多内容
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
5.6
作者：
Connors J;Bell MR;Marcy J;Kutzler M;Haddad EK
通讯作者：
Haddad EK
影响因子：
13.8
作者：
Kreps S;Prasad S;Brownstein JS;Hswen Y;Garibaldi BT;Zhang B;Kriner DL
通讯作者：
Kriner DL
DOI：
10.15585/mmwr.mm6938e1
发表时间：
2020-09-25
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Delahoy MJ;Whitaker M;O'Halloran A;Chai SJ;Kirley PD;Alden N;Kawasaki B;Meek J;Yousey-Hindes K;Anderson EJ;Openo KP;Monroe ML;Ryan PA;Fox K;Kim S;Lynfield R;Siebman S;Davis SS;Sosin DM;Barney G;Muse A;Bennett NM;Felsen CB;Billing LM;Shiltz J;Sutton M;West N;Schaffner W;Talbot HK;George A;Spencer M;Ellington S;Galang RR;Gilboa SM;Tong VT;Piasecki A;Brammer L;Fry AM;Hall AJ;Wortham JM;Kim L;Garg S;COVID-NET Surveillance Team
通讯作者：
COVID-NET Surveillance Team
影响因子：
6.2
作者：
Jacobson RM;Agunwamba AA;St Sauver JL;Finney Rutten LJ
通讯作者：
Finney Rutten LJ